These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2876669)

  • 41. Current concepts in clinical therapeutics: peptic ulcer disease.
    Siepler JK; Mahakian K; Trudeau WT
    Clin Pharm; 1986 Feb; 5(2):128-42. PubMed ID: 2869852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The association of ranitidine and sucralfate in the short-term treatment of duodenal ulcers, as compared to other forms of treatment.
    Magnanelli M; Belvisi A; Toninelli A; Matergi M; Camarri E
    Int J Tissue React; 1984; 6(2):189-93. PubMed ID: 6329980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sucralfate compared with ranitidine in the short-term healing of duodenal ulcers.
    Lam KT; Lai ST; Kan YS; Chan AY
    J Int Med Res; 1985; 13(6):338-41. PubMed ID: 3841079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Which drug for peptic ulcer?].
    Hameeteman W; Tytgat GN
    Ned Tijdschr Geneeskd; 1985 Aug; 129(35):1673-6. PubMed ID: 2864643
    [No Abstract]   [Full Text] [Related]  

  • 45. Twenty-four-hour intragastric pH-metry: H2-receptor antagonist restoration of nightly gastric spontaneous alkalinization in duodenal ulcer healing.
    Bianco A; Cagossi M; Piraccini R; Greco AV
    Riv Eur Sci Med Farmacol; 1992; 14(5):281-91. PubMed ID: 1364062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New drugs. H2 receptor antagonists--cimetidine and ranitidine.
    Feely J; Wormsley KG
    Br Med J (Clin Res Ed); 1983 Feb; 286(6366):695-7. PubMed ID: 6130817
    [No Abstract]   [Full Text] [Related]  

  • 47. Changes in mucosal levels of transforming growth factor-alpha from the oxyntic region and ulcer site during duodenal ulcer healing with ranitidine or sucralfate.
    Louw JA; Modlin IM; Tang L; Young GO; Lucke W; Marks IN
    J Int Med Res; 1998; 26(2):82-6. PubMed ID: 9602986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short- and long-term studies of duodenal ulcer with sucralfate.
    Moshal MG; Spitaels JM; Khan F
    J Clin Gastroenterol; 1981; 3(Suppl 2):159-61. PubMed ID: 6895644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
    Chan FK; Sung JJ; Lee YT; Leung WK; Chan LY; Yung MY; Chung SC
    Am J Gastroenterol; 1997 Mar; 92(3):442-5. PubMed ID: 9068465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety profile of long-term H2-antagonist therapy.
    Lewis JH
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():49-57. PubMed ID: 1679672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acid-secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after treatment with sucralfate or ranitidine.
    Marks IN; Young GO; Tigler-Wybrandi NA; Bridger S; Newton KA
    Am J Med; 1989 Jun; 86(6A):145-7. PubMed ID: 2735330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of duodenal ulcer with famotidine].
    Schütze K; Hentschel E; Reichel W; Kerstan E
    Wien Med Wochenschr; 1987 Sep; 137(17):409-11. PubMed ID: 2891224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The other option in peptic ulcer therapy.
    Halter F
    S Afr Med J; 1984 Jun; 65(25):996-1000. PubMed ID: 6374932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current directions in the treatment of gastric and duodenal ulcers].
    Fellus R
    Dakar Med; 1988; 33(1-4):42-4. PubMed ID: 2908566
    [No Abstract]   [Full Text] [Related]  

  • 55. Randomised double blind placebo controlled clinical trial of sucralfate and ranitidine in chronic duodenal ulcer.
    Nair KV; Ramachandran TM; Thomas V; Rajindranath T
    J Assoc Physicians India; 1990 Mar; 38(3):211-2. PubMed ID: 2202705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longer relapse-free period after sucralfate than after H2-blocker treatment of duodenal and gastric ulcers.
    Domschke S; Domschke W
    Am J Med; 1991 Aug; 91(2A):74S-83S. PubMed ID: 1679297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective drugs in the treatment of gastroduodenal ulcer disease.
    Koelz HR
    Scand J Gastroenterol Suppl; 1986; 125():156-64. PubMed ID: 3547612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drugs for treatment of peptic ulcers.
    Med Lett Drugs Ther; 1997 Jan; 39(991):1-4. PubMed ID: 8996458
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapy of ulcer recurrence after vagotomy of oxyntic cells with sucralfate].
    Fernández Dovale M; Docobo Durántez F; Lozano Crivell M
    Rev Esp Enferm Dig; 1990 Feb; 77(2):109-12. PubMed ID: 2346677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
    Thomson AB
    Hepatogastroenterology; 1990 Jul; 37 Suppl 1():18-28. PubMed ID: 1976583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.